|
Back to Home » June 2020 News » New Small Cell Lung Cancer Drug Accepted for TGA Evaluation Under Project Orbis |
New Small Cell Lung Cancer Drug Accepted for TGA Evaluation Under Project Orbis |
June 03, 2020
Key Highlights TGA has granted provisional designation for new drug Lurbinectedin based on encouraging Phase 2 results and high unmet medical need A marketing application has now been accepted by the TGA under provisional evaluation pathway Lurbinectedin has received priority review under...
Source URL: https://www.prnewswire.com:443/news-releases/new-small-cell-lung-cancer-drug-accepted-for-tga-evaluation-under-project-orbis-301069865.html
|
|
|
|
